written on 21.03.2014

CHMP grants label extensions to Novo Nordisk and Roche


Furthermore, the committee gave a positive opinion for a label extension of the Denmark-based firm's the once-daily, long-acting basal insulin Tresiba (insulin degludec), to include use in combination with GLP-1 receptor agonists in patients with type 2…

Latest Reports